Montalban X - Search Results

1

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.

Coles AJ, Jones JL, Vermersch P, Traboulsee A, Bass AD, Boster A, Chan A, Comi G, Fernández Ó, Giovannoni G, Kubala Havrdova E, LaGanke C, Montalban X, Oreja-Guevara C, Piehl F, Wiendl H, Ziemssen T. Coles AJ, et al. Among authors: montalban x. Mult Scler. 2022 Apr;28(5):842-846. doi: 10.1177/13524585211061335. Epub 2021 Dec 9. Mult Scler. 2022. PMID: 34882037 Free PMC article. Review.

2

Treatment of relapsing-remitting multiple sclerosis with natural interferon beta: a multicenter, randomized clinical trial.

Fernández O, Antiquëdad A, Arbizu T, Capdevíla A, de Castro P, Correa de Sa JC, García-Merino JA, Izquierdo G, Magalhaes A, Montalbán X, et al. Fernández O, et al. Among authors: montalban x. Mult Scler. 1995;1 Suppl 1:S67-9. Mult Scler. 1995. PMID: 9345404 Clinical Trial.

3

Evolution of multiple sclerosis lesions on serial contrast-enhanced T1-weighted and magnetization-transfer MR images.

Rovira A, Alonso J, Cucurella G, Nos C, Tintoré M, Pedraza S, Rio J, Montalban X. Rovira A, et al. Among authors: montalban x. AJNR Am J Neuroradiol. 1999 Nov-Dec;20(10):1939-45. AJNR Am J Neuroradiol. 1999. PMID: 10588122 Free PMC article.

4

[Natural interferon-beta in the treatment of relapsing-remitting multiple sclerosis: a multicenter, randomized, MRI-based, phase II clinical trial].

Fernández O, Antigüedad A, Arbizu T, Burgués S, Capdevila A, de Castro P, Correa de Sá JC, García-Merino JA, Izquierdo G, Magalhaes A, Montalbán X, Zarranz JJ. Fernández O, et al. Among authors: montalban x. Rev Neurol. 1999 Dec 16-31;29(12):1093-9. Rev Neurol. 1999. PMID: 10652728 Clinical Trial. Spanish.

5

Interferon beta-1b treatment in patients with relapsing--remitting multiple sclerosis under a standardized protocol in Spain.

Arbizu T, Alvarez-Cermeño JC, Decap G, Fernández O, Uría DF, García Merino A, Izquierdo G, Montalbán X. Arbizu T, et al. Among authors: montalban x. Acta Neurol Scand. 2000 Oct;102(4):209-17. doi: 10.1034/j.1600-0404.2000.102004209.x. Acta Neurol Scand. 2000. PMID: 11071104

6

Durán I, Martínez-Cáceres EM, Brieva L, Tintoré M, Montalban X. Durán I, et al. Among authors: montalban x. Mult Scler. 2001 Jun;7(3):151-6. doi: 10.1177/135245850100700303. Mult Scler. 2001. PMID: 11475437

7

Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS.

Tintoré M, Rovira A, Brieva L, Grivé E, Jardí R, Borrás C, Montalban X. Tintoré M, et al. Among authors: montalban x. Mult Scler. 2001 Dec;7(6):359-63. doi: 10.1177/135245850100700603. Mult Scler. 2001. PMID: 11795456

8

Two-year follow-up study of primary and transitional progressive multiple sclerosis.

Ingle GT, Stevenson VL, Miller DH, Leary SM, Rovaris M, Barkhof F, Brochet B, Dousset V, Filippi M, Montalban X, Kalkers NF, Polman CH, Rovira A, Thompson AJ. Ingle GT, et al. Among authors: montalban x. Mult Scler. 2002 Apr;8(2):108-14. doi: 10.1191/1352458502ms778oa. Mult Scler. 2002. PMID: 11990866

9

Workshop on primary progressive multiple sclerosis: meeting summary.

Montalban X, Thompson AJ. Montalban X, et al. Mult Scler. 2002 Apr;8(2):177-8. doi: 10.1191/1352458502ms792xx. Mult Scler. 2002. PMID: 11990876 No abstract available.

10

Expression of chemokine receptors in the different clinical forms of multiple sclerosis.

Martínez-Cáceres EM, Espejo C, Brieva L, Pericot I, Tintoré M, Sáez-Torres I, Montalban X. Martínez-Cáceres EM, et al. Among authors: montalban x. Mult Scler. 2002 Oct;8(5):390-5. doi: 10.1191/1352458502ms841oa. Mult Scler. 2002. PMID: 12356205

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

786 results

Search Page